Jiangsu Hengrui Medicine tops the list with a 10.7% weighting.
Hang Seng Indexes has launched the Hang Seng Shanghai-Shenzhen-Hong Kong Innovative Drug Select 50 Index, which aims to meet the needs of product issuers to create index-linked products in the drug industry, according to a press release.
The cross-market index comprises 50 stocks in pharmaceutical and related industries that demonstrate high levels of investment in research & development and strong momentum performances. All constituents are listed in Shanghai, Shenzhen, or Hong Kong.
As of 30 March, the top 10 constituent company weightings are Jiangsu Hengrui Medicine (10.7%), Changchun High & New Technology Industries Inc. (7.39%), Sino Biopharmaceutical (7.21%), Wuxi Biologics (Cayman) (6.98%), CSPC Pharmaceutical Group Ltd. (6.83%), WuXi Apptec (6.79%), Chongqing Zhifei Biological Products (4.23%), Lepu Medical Technology (Beijing) (4.03%), Walvax Biotechnology (4%), and Hualan Biological Engineering (3.56%)
Eligible companies are required to have an average daily turnover of at least $20m for Hong Kong-listed securities, and at least $21.85m (CNY20m) for A-shares over the past six months.
Companies should be classified under chemical medicines or biotechnology and are required to publicly disclose the commercialisation of drug products. Organisations engaged in contract research (CRO), contract manufacturing (CMO) and contract development and manufacturing (CDMO) can be included in the index.
Photo courtesy of Pexels.com
Do you know more about this story? Contact us anonymously through this link.